Intra-Cellular Therapies
ITCI
$66.80
Share price
1.67%
Change (1 day)
2.92%
Change (1 year)
Categories
Earnings for Intra-Cellular Therapies (ITCI)
Earnings in 2023 (TTM): -$0.14 B
According to Intra-Cellular Therapies's latest financial reports the company's current earnings (TTM) are -$0.14 B. In 2022 the company made an earning of -$0.26 B an increase over its 2021 earnings that were of -$0.29 B.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Intra-Cellular Therapies from 2014 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2023 (TTM)  | -$0.14 B | -45.74% |
| 2022 | -$0.26 B | -9.81% |
| 2021 | -$0.29 B | 25.17% |
| 2020 | -$0.23 B | 53.66% |
| 2019 | -$0.15 B | -4.77% |
| 2018 | -$0.16 B | 56.96% |
| 2017 | -$98.84 M | -14.33% |
| 2016 | -$0.12 B | 10.09% |
| 2015 | -$0.11 B | 241.45% |
| 2014 | -$30.69 M |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | -$0.13 B | -13.38% | 🇺🇸 USA |
 MediciNova MNOV | -$8.57 M | -93.84% | 🇺🇸 USA |
 Curis CRIS | -$43.93 M | -68.41% | 🇺🇸 USA |